Literature DB >> 16517973

Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Irene Vejgaard Sorensen1, Claus Fenger, Henrik Winther, Niels T Foged, Ulrik Lademann, Nils Brünner, Pernille A Usher.   

Abstract

The aim of this study was to evaluate seven anti-TIMP-1 (tissue inhibitor of metalloproteinase-1) monoclonal antibodies by immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded (FFPE) tissue. Detection of the TIMP-1 protein was studied by IHC in FFPE human archival normal and neoplastic samples. Indirect IHC technique was used, and the seven antibodies (clones VT1, VT2, VT4, VT5, VT6, VT7, and VT8) were tested in various concentrations using different pretreatment protocols. All seven VT antibodies specifically immunostained the cytoplasm of islets of Langerhans cells in normal pancreas, epithelial cells of hyperplastic prostate, tumor cells of medullary thyroid carcinoma, and fibroblast-like cells of malignant melanoma. Specificity of the anti-TIMP-1 antibodies was confirmed by several controls, e.g., Western blotting on proteins extracted from FFPE tissue showed that the VT7 antibody reacted specifically with a protein band of approximately 28 kDa, corresponding to the molecular mass of TIMP-1. However, sensitivity varied with the different antibodies. Use of heat-induced epitope retrieval (HIER) and the VT7 clone applied at low concentrations demonstrated more intense immunoreactivity with the TIMP-1-positive cell types compared to the other six clones. Furthermore, when tested on a range of normal and neoplastic endocrine tissues, the VT7 clone demonstrated immunoreactivity with all neuroendocrine cell types. In conclusion, all seven antibodies detected TIMP-1 protein in various normal and neoplastic FFPE tissues, but one clone, VT7, was superior for IHC staining of TIMP-1 in FFPE tissue sections when using HIER.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517973      PMCID: PMC3957804          DOI: 10.1369/jhc.5A6896.2006

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  43 in total

Review 1.  Antigen retrieval techniques: current perspectives.

Authors:  S R Shi; R J Cote; C R Taylor
Journal:  J Histochem Cytochem       Date:  2001-08       Impact factor: 2.479

2.  High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.

Authors:  M N Holten-Andersen; R W Stephens; H J Nielsen; G Murphy; I J Christensen; W Stetler-Stevenson; N Brünner
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

Review 3.  Matrix metalloproteinases in tumour invasion and metastasis.

Authors:  S Curran; G I Murray
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

4.  Primary structure and cDNA cloning of human fibroblast collagenase inhibitor.

Authors:  D F Carmichael; A Sommer; R C Thompson; D C Anderson; C G Smith; H G Welgus; G P Stricklin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

Review 5.  Tissue inhibitor of metalloproteinases-1 in breast cancer.

Authors:  S Ø Würtz; A-S Schrohl; N Møller Sørensen; U Lademann; I J Christensen; H Mouridsen; N Brünner
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

6.  Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.

Authors:  Daniela Massi; Alessandro Franchi; Sheyda Ketabchi; Milena Paglierani; Nicola Pimpinelli; Marco Santucci
Journal:  Hum Pathol       Date:  2003-01       Impact factor: 3.466

7.  Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Pituitary Adenomas: Possible Markers of Neuroendocrine Cells.

Authors:  Tatsuo Tomita
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

8.  Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival.

Authors:  Elise Lambert; Cédric Boudot; Zahra Kadri; Mahdhia Soula-Rothhut; Marie-Line Sowa; Patrick Mayeux; William Hornebeck; Bernard Haye; Emmanuelle Petitfrere
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

9.  TIMP1 and adverse prognosis in non-small cell lung cancer.

Authors:  K M Fong; Y Kida; P V Zimmerman; P J Smith
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

10.  Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro.

Authors:  C M Alexander; Z Werb
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  14 in total

Review 1.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

2.  TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

Authors:  Christina Bjerre; Lena Vinther; Kirstine C Belling; Sidse Ø Würtz; Rachita Yadav; Ulrik Lademann; Olga Rigina; Khoa Nguyen Do; Henrik J Ditzel; Anne E Lykkesfeldt; Jun Wang; Henrik Bjørn Nielsen; Nils Brünner; Ramneek Gupta; Anne-Sofie Schrohl; Jan Stenvang
Journal:  Tumour Biol       Date:  2013-07-24

3.  Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.

Authors:  Jesper Kolenda; Stine Skov Jensen; Charlotte Aaberg-Jessen; Karina Christensen; Claus Andersen; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

4.  Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Rikke Kølby Christensen; Annette Bartels; Nils Brünner; Anders Jakobsen
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430

5.  TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.

Authors:  Xiaohong Deng; Louise Fogh; Ulrik Lademann; Vibeke Jensen; Jan Stenvang; Huanming Yang; Nils Brünner; Anne-Sofie Schrohl
Journal:  Tumour Biol       Date:  2013-01-22

6.  In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.

Authors:  Marius I Ilie; Sandra Lassalle; Elodie Long-Mira; Véronique Hofman; Joséphine Zangari; Gilles Bénaim; Alexandre Bozec; Nicolas Guevara; Juliette Haudebourg; Isabelle Birtwisle-Peyrottes; José Santini; Patrick Brest; Paul Hofman
Journal:  Virchows Arch       Date:  2013-07-27       Impact factor: 4.064

7.  Immunohistochemical expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in invasive breast carcinoma.

Authors:  Suada Kuskunović; Svjetlana Radović; Mirsad Dorić; Ajna Hukić; Mirsad Babić; Ivana Tomić; Ivan Selak
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

8.  Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.

Authors:  Charlotte Aaberg-Jessen; Karina Christensen; Hanne Offenberg; Annette Bartels; Tanja Dreehsen; Steinbjørn Hansen; Henrik Daa Schrøder; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

9.  Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Authors:  Warner Alpízar-Alpízar; Ole Didrik Laerum; Ib J Christensen; Kjell Ovrebo; Arne Skarstein; Gunilla Høyer-Hansen; Michael Ploug; Martin Illemann
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

10.  Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions.

Authors:  Vikram Deshpande; Richard O Hynes; Steffen Rickelt; Charlene Condon; Miyeko Mana; Charlie Whittaker; Christina Pfirschke; Jatin Roper; Deepa T Patil; Ian Brown; Anthony R Mattia; Lawrence Zukerberg; Qing Zhao; Runjan Chetty; Gregory Y Lauwers; Azfar Neyaz; Lieve G J Leijssen; Katherine Boylan; Omer H Yilmaz
Journal:  Clin Cancer Res       Date:  2019-12-18       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.